Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


Published ahead of print on April 2, 2008
J Am Soc Nephrol 19: 844-846, 2008
© 2008 American Society of Nephrology
doi: 10.1681/ASN.2008010110
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ASN.2008010110v1
19/5/844    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Bauer, C.
Right arrow Articles by Hostetter, T. H.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bauer, C.
Right arrow Articles by Hostetter, T. H.

Clinical Commentary

Staging of Chronic Kidney Disease: Time for a Course Correction

Carolyn Bauer, Michal L. Melamed and Thomas H. Hostetter

Department of Medicine, Division of Nephrology, Albert Einstein College of Medicine, Bronx, New York

Correspondence: Dr. Thomas H. Hostetter, Room 615, Ullmann Building, 1300 Morris Park Avenue, Bronx, NY 10461. Phone: 718-430-3158; Fax: 718-430-896; E-mail: thostett{at}aecom.yu.edu

Awareness of chronic kidney disease (CKD) has increased in part because of the definitions and treatment guidelines set out by Kidney Disease Outcomes Quality Initiative (KDOQI); however, the staging system set forth by these guidelines has led to several problems and unforeseen consequences. Stages 1 and 2 CKD are difficult to determine using the standard Modification of Diet in Renal Disease (MDRD) estimation of GFR, and their clinical significance in the absence of other risk factors is unclear. Just because microalbuminuria in people without diabetes is a cardiovascular risk factor does not make it kidney disease. Most patients who receive a diagnosis of stage 3 CKD (GFR between 30 and 59 ml/min) are elderly people, and the vast majority of these patients will die before they reach ESRD. The staging system needs to be modified to reflect the severity and complications of CKD. It is suggested that stages 1 and 2 be eliminated and stages 3, 4, and 5, be simply termed moderate impairment, severe impairment, and kidney failure, respectively. In addition, age should be a modifying factor, especially in moderate kidney impairment. These changes would allow identification and treatment of clinically relevant disease and avoidance of what can seem exaggerated prevalence estimates.




This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
A. S. Levey, L. A. Stevens, and J. Coresh
Reply
Nephrol. Dial. Transplant., August 1, 2008; 23(8): 2696 - 2698.
[Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
E. Noble, D. W. Johnson, N. Gray, P. Hollett, C. M. Hawley, S. B. Campbell, D. W. Mudge, and N. M. Isbel
The impact of automated eGFR reporting and education on nephrology service referrals
Nephrol. Dial. Transplant., July 16, 2008; (2008) gfn385v1.
[Abstract] [Full Text] [PDF]


HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673